Anti-F13A1 antibody produced in rabbit
SIGMA/HPA001804 - Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Synonym: Anti-Coagulation factor XIII A chain precursor antibody produced in rabbit; Anti-Coagulation factor XIIIa antibody produced in rabbit; Anti-
Product Type: Chemical
| antibody form | affinity isolated antibody |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | polyclonal |
| conjugate | unconjugated |
| enhanced validation | orthogonal RNAseq Learn more about Antibody Enhanced Validation ![]() |
| form | buffered aqueous glycerol solution |
| immunogen sequence | LNVTSVHLFKERWDTNKVDHHTDKY |
| product line | Prestige Antibodies® Powered by Atlas Antibodies |
| Quality Level | 100 ![]() |
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | −20°C |
| target post-translational modification | unmodified |
| technique(s) | immunohistochemistry: 1:200-1:500 |
| UniProt accession no. | P00488 ![]() |
| Application: | Applications in which this antibody has been used successfully, and the associated peer-reviewed papers, are given below. Western Blotting (1 paper) ![]() |
| Biochem/physiol Actions: | During blood coagulation, thrombin produces activated factor XIIIa (F13A1) from proenzyme, a transglutaminase, in presence of calcium ions and fibrin. Activated F13A1 accelerates the cross-linking reaction between fibrin monomers and between fibrin and A2- plasmin inhibitor. This cross linking reaction finally forms intermolecular ε-(γ-glutamyl) lysine bonds between the y chains and α chains of fibrin monomers followed by fibrin clot. It also catalyzes the cross-linking of fibronectin to fibrin or to collagen reaction which is an essential step for wound healing. Deficiency of F13A1 causes a severe lifelong bleeding tendency, defective wound healing, and habitual abortion. |
| Disclaimer: | Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals. |
| Features and Benefits: | Prestige Antibodies® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section. Every Prestige Antibody is tested in the following ways: • IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues. • Protein array of 364 human recombinant protein fragments. |
| General description: | F13A1 (coagulation factor XIII A chain), a zymogen C, is a fibrin stabilizing glycoprotein. Coagulation factor XIII exists as a tetramer (A2B2) consisting of non-covalently bonded two A and two B subunits. F13A1 plays crucial role in termination of blood coagulation and and the fibrinolysis regulation. |
| Immunogen: | Coagulation factor XIII A chain precursor recombinant protein epitope signature tag (PrEST) |
| Legal Information: | Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany |
| Other Notes: | Corresponding Antigen APREST84520 |
| Physical form: | Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | −20°C |
| UNSPSC | 12352203 |

